Pharmaceutical Patents

Life Sciences Update -- May 2013: Baker & McKenzie

by Baker & McKenzie Australia on 5/3/2013

Increased Regulation of Interactions with Healthcare Professionals - In an effort to increase the transparency of interactions between pharmaceutical companies and health care professionals the new (17th) edition of...more

Court Report -- April 22, 2013

by Sherri Oslick | McDonnell Boehnen Hulbert & Berghoff LLP on 4/22/2013

About Court Report: Each week we will report briefly on recently filed biotech and pharma cases. - Depomed, Inc. v. Endo Pharmaceuticals Inc. 3:13-cv-02467; filed April 17, 2013 in the District Court of New Jersey:...more

Court Report -- April 14, 2013

by Sherri Oslick | McDonnell Boehnen Hulbert & Berghoff LLP on 4/15/2013

About Court Report: Each week we will report briefly on recently filed biotech and pharma cases. Shire LLC v. Neos Therapeutics, Inc. - 3:13-cv-01452; filed April 11, 2013 in the Northern District of...more

Key Recommendations From The Australian Pharmaceutical Patents Review

by Carol Burnton, James Cherry | Freehills Patent Attorneys on 4/11/2013

The Australian Government has continued with the trend of reviewing Australian patent law by commissioning a review of laws relating to patents for medicines ie pharmaceutical patents. The Pharmaceutical Patents Review Panel...more

Court Report -- April 07, 2013

by Sherri Oslick | McDonnell Boehnen Hulbert & Berghoff LLP on 4/8/2013

In This Issue: Novartis Pharmaceuticals Corp. et al. v. Noven Pharmaceuticals Inc. et al.; Purdue Pharmaceutical Products L.P. et al. v. Dr. Reddy's Laboratories, Inc. et al.; Taro Pharmaceuticals North America, Inc....more

Supreme Court of India Denies Novartis Patent Application

by Amita Gopinath | Miller Canfield on 4/4/2013

In a landmark judgment delivered on April 1, 2013, the Supreme Court of India dismissed an appeal by Novartis AG, a Swiss pharmaceutical giant, to win patent protection in India for its cancer drug Glivec. The polarizing...more

Idenix seen as unlikely to prevail against Gilead in HCV patent interference

by Snell & Wilmer L.L.P. on 4/4/2013

Idenix Pharmaceuticals (NASDAQ:IDIX) faces an uphill battle to sufficiently demonstrate enablement in its ongoing patent interference against Gilead Sciences (NASDAQ:GILD) regarding their respective hepatitis C (HCV)...more

Litigation Alert: U.S. Supreme Court to Weigh In on Reverse Payment Deals

by Melanie Mayer, David Tellekson | Fenwick & West LLP on 4/3/2013

On March 25, 2013, the U.S. Supreme Court heard oral argument in FTC v. Actavis, Inc.,1 which is on appeal from the U.S. Court of Appeals for the Eleventh Circuit. This case addresses a type of patent litigation settlement...more

A Cure For Antitrust Standing?

by Deirdre McInerney, Barbara Sicalides | Pepper Hamilton LLP on 3/7/2013

Recently, the Third Circuit reexamined the test for antitrust standing in Ethypharm S. A. France v. Abbott Laboratories. The importance of the opinion, however, lies not just in the court’s affirmation of the multifactor test...more

Will FTC Chairman Leibowitz’s Departure Change The Enforcement Landscape?

by Barak Bassman, Daniel Boland, Deirdre McInerney, Barbara Sicalides | Pepper Hamilton LLP on 3/7/2013

After three years at the helm of the Federal Trade Commission (FTC), Chairman Jon Leibowitz stepped down. Without a doubt Chairman Leibowitz has been a visible and relentless advocate for restricting pay-for-day or reverse...more

February 2013: Japan Litigation Update

by Quinn Emanuel Urquhart & Sullivan, LLP on 2/19/2013

In This Issue: - Japanese Court’s Ruling Limits Scope of Contributory Infringement in Pharmaceutical Patents - Criminalization of Illegal Music and Video Downloads....more

Home

Legal News

Find a Lawyer

Browse Subjects

Subscribe

Pro Services

For Reporters